Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$431.5m

Esperion Therapeutics Future Growth

Future criteria checks 5/6

Esperion Therapeutics is forecast to grow earnings and revenue by 67.6% and 28.3% per annum respectively while EPS is expected to grow by 68.2% per annum.

Key information

67.6%

Earnings growth rate

68.2%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate28.3%
Future return on equityn/a
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 08

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13

Esperion Therapeutics: Strategically Positioned To Grow

Aug 16

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Earnings and Revenue Growth Forecasts

NasdaqGM:ESPR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202647412386246
12/31/20254017383748
12/31/2024327-5755-299
9/30/2024295-87-26-26N/A
6/30/2024278-98-10-10N/A
3/31/2024230-87-27-27N/A
12/31/2023116-209-135-135N/A
9/30/2023103-208-141-141N/A
6/30/202388-222-164-164N/A
3/31/202381-239-190-190N/A
12/31/202275-234-175-175N/A
9/30/202272-243-190-190N/A
6/30/202267-258-216-216N/A
3/31/202289-235-214-214N/A
12/31/202178-269-264-264N/A
9/30/202173-308-287-275N/A
6/30/202162-325-305-292N/A
3/31/2021234-156-118-105N/A
12/31/2020228-144-99-85N/A
9/30/2020219-101-67-67N/A
6/30/2020216-84-39-38N/A
3/31/20205-263-232-231N/A
12/31/2019148-97-71-70N/A
9/30/2019147-95-50-49N/A
6/30/2019146-77-29-29N/A
3/31/2019145-68-14-14N/A
12/31/2018N/A-202-149-149N/A
9/30/2018N/A-180-155-155N/A
6/30/2018N/A-175N/A-153N/A
3/31/2018N/A-173N/A-140N/A
12/31/2017N/A-167N/A-131N/A
9/30/2017N/A-158N/A-113N/A
6/30/2017N/A-130N/A-91N/A
3/31/2017N/A-101N/A-72N/A
12/31/2016N/A-75N/A-48N/A
9/30/2016N/A-59N/A-40N/A
6/30/2016N/A-55N/A-37N/A
3/31/2016N/A-53N/A-39N/A
12/31/2015N/A-50N/A-38N/A
9/30/2015N/A-46N/A-38N/A
6/30/2015N/A-43N/A-35N/A
3/31/2015N/A-40N/A-32N/A
12/31/2014N/A-36N/A-32N/A
9/30/2014N/A-37N/A-31N/A
6/30/2014N/A-32N/A-27N/A
3/31/2014N/A-30N/A-25N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ESPR is expected to become profitable in the next 3 years.

Revenue vs Market: ESPR's revenue (28.3% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ESPR's revenue (28.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:04
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Esperion Therapeutics, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Thomas ShraderBTIG
Kristen KluskaCantor Fitzgerald & Co.